Effect of Silymarin on Non Alcoholic Steatohepatitis

INTERVENTION: Contorol group: placebo Intervention 1: Intervention group: 140 mg of Silymarin BID during 6 month. Intervention 2: Contorol group: placebo. Intervention group: 140 mg of Silymarin BID during 6 month Placebo Treatment ‐ Drugs CONDITION: Fatty (change of) liver, not elsewhere classified Non alcocholic steatohepatitis. ; Fatty (change of) liver, not elsewhere classified PRIMARY OUTCOME: ALT. Timepoint: Before and 6 months after the therapy. Method of measurement: laboratory. AST. Timepoint: Before and 6 months after the therapy. Method of measurement: laboratory. Sonographic markers. Timepoint: Before and 6 months after the therapy. Method of measurement: by Radiologist. SECONDARY OUTCOME: BMI. Timepoint: Before and 6 months after the therapy. Method of measurement: Weight(kg)/height^2(m2). FBS. Timepoint: before and 6 months after the therapy. Method of measurement: laboratory. TG. Timepoint: Before and 6 months after the therapy. Method of measurement: laboratory. Weight. Timepoint: Before and 6 month after the therapy. Method of measurement: balance. INCLUSION CRITERIA: Including criteria: older than 20 years with nonalcoholic‐ fatty liver disease and liver enzymes> 50 and proportion of ALT/ AST> 1 Excluding criteria: using drugs that affect liver tests during the last 2 months, viral hepatitis, hemochromatosis, autoimmune hepatitis, cirrhosis, diabetes mellitus, alcohol dependency, pregnancy, breast feeding, and infectious diseases